---
title: "Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299648083.md"
description: "The latest findings support Avalyn's strategy of administering known antifibrotic drugs directly to the lungs for increased local impact, reducing systemic exposure, and enhancing tolerance."
datetime: "2026-09-21T13:02:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299648083.md)
  - [en](https://longbridge.com/en/news/299648083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299648083.md)
generator: "portal-rs"
---

# Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

The latest findings support Avalyn's strategy of administering known antifibrotic drugs directly to the lungs for increased local impact, reducing systemic exposure, and enhancing tolerance.

### Related Stocks

- [AVLN.US](https://longbridge.com/en/quote/AVLN.US.md)

## Related News & Research

- [Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levels](https://longbridge.com/en/news/299663715.md)
- [Avalyn Pharma Director Robert J. Meyer files initial beneficial ownership statement](https://longbridge.com/en/news/299360082.md)
- [ROI-Oil's new problem isn't supply. It's logistics: Bousso](https://longbridge.com/en/news/300903866.md)
- [ConocoPhillips sees oil price floor rising to $70 a barrel, chairman says](https://longbridge.com/en/news/300916819.md)
- [TECHNICALS-US oil may retest support at $88.78](https://longbridge.com/en/news/300892493.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**